Abstract：Objective: To evaluate the effects of Cadonilimab on immune function and cell proliferation/apoptosis-related proteins in patients with recurrent/advanced cervical cancer. Methods: A total of 48 patients with recurrent/advanced cervical cancer treated in our hospital from October 2022 to May 2024 were selected. All patients received Cadonilimab treatment. Patient efficacy, adverse reactions, and survival rates were statistically analyzed during the follow-up period. Changes in cellular immune function, serum tumor markers [squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1)], expression levels of cell proliferation/apoptosis-related proteins [tumor protein P53 (P53), Bcl-2-associated X protein (Bax), programmed cell death factor 5 (PDCD5), epidermal growth factor receptor (EGFR), cytosolic thymidine kinase 1 (TK1)], and quality of life [Functional Assessment of Cancer Therapy-Cervical cancer (FACT-Cx) scores] were observed before and after treatment. Results: The objective response rate (ORR) and the disease control rate (DCR) were 68.75% (33/48) and 81.25% (39/48) respectively in the 48 patients with recurrent/advanced cervical cancer. After treatment, the levels of CD3+, CD4+ T lymphocytes, and CD4+/CD8+ ratios were higher than before treatment (P<0.05). The serum levels of SCCA, CEA, CA125, and CYFRA21-1 were lower after treatment compared with before treatment (P<0.05). The serum expression levels of P53, Bax, and PDCD5 were higher after treatment, while expression levels of EGFR and TK1 were lower than before treatment (P<0.05). The scores across all 5 dimensions of the FACT-Cx scale were higher after treatment (P<0.05). With a median follow-up time of 11.354 months (95% CI: 10.920-11.788), the 1-year overall survival (OS) rate was 81.25% (39/48). The incidence of grade 3-4 adverse reactions was 58.33% (28/48); grade 1-2 adverse reactions were gradually resolved after appropriate management. Conclusion: Cadonilimab-based regimens can improve cellular immune function, reduce serum tumor marker levels, and modulate the expression of cell proliferation/apoptosis-related proteins in patients with recurrent/advanced cervical cancer, which is associated with higher survival rates and a manageable safety profile.
柏家英, 杨英捷, 李凤虎. 卡度尼利单抗对复发性/晚期宫颈癌患者T淋巴细胞亚群水平细胞增殖凋亡相关蛋白的影响[J]. 河北医学, 2026, 32(2): 335-341.
BAI Jiaying, YANG Yingjie. Effects of Cadonilimab on T Lymphocyte Subsets and Cell Proliferation/ Apoptosis-Related Proteins in Patients with Recurrent/Advanced Cervical Cancer. HeBei Med, 2026, 32(2): 335-341.
[1] 中国医师协会微无创医学专业委员会妇科肿瘤学组,山东省抗癌协会妇科肿瘤分会.复发性子宫颈癌综合诊治中国专家共识(2022年版)[J].中华肿瘤防治杂志,2022,29(24):1715-1724. [2] Berek JS,Matias-Guiu X,Creutzberg C,et al.FIGO staging of endometrial cancer:2023[J].Int Gynaecol Obstet,2023,162(2):383-394. [3] 段梅艳,陈超,李丹丹.贝伐珠单抗联合TP方案同步放疗治疗复发性宫颈癌的疗效观察[J].实用癌症杂志,2024,39(9):1473-1476. [4] Wu XH,Ji JF,Lou HM,et al.Efficacy and safety of cadonilimab,an anti-PD-1/CTLA4 bi-specific antibody,inpreviously treated recurrent or metastatic(R/M) cervical cancer:a multicenter,open-label,single-arm,phaseⅡ rial(075)[J].Gynecol Oncol,2022,166(Suppl1):47-48. [5] 中国抗癌协会妇科肿瘤专业委员会.子宫颈癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):474-489. [6] Chen WJ,Kong DM,Li L.Prognostic value of ECOG performance status and gleason score in the survival of castration-resistant prostate cancer:a systematic review[J].Asian Androl,2021,23(2):163-169. [7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J],循证医学,2004,4(2):85-111. [8] 吴仪,郑筱萸.药品不良反应报告和监测管理办法[J].司法业务文选,2011,22(22):7-18. [9] 李金兰,潘勇,曾媚姿,等.卡度尼利单抗不良反应临床特点分析[J].中国新药杂志,2024,33(6):619-624. [10] Long B,Zhou H,Yu Z,et al.Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma:a multicenter,phase 2 study[J].Med,2025,6(3):100531. [11] Wu X,Sun Y,Yang H,et al.Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent,recurrent,or metastatic cervical cancer (COMPASSION-16):a randomised,double-blind,placebo-controlled phase 3 trial in China[J].Lancet,2024,404(10463):1668-1676. [12] Pawar JS,Mustafa S,Ghosh I.Chrysin and capsaicin induces premature senescence and apoptosis via mitochondrial dysfunction and p53 elevation in cervical cancer cells[J].Saudi Biol Sci,2022,29(5):3838-3847, [13] Zhang M,Xin L,Cheng B,et al.Clinical value analysis of serum TK1,SCC-Ag,and MUC-1 in the diagnosis and prognosis evaluation of cervical cancer[J].Altern Ther Health Med,2023,29(8):788-792, [14] 涂云霞,华金仁,刘荣芳,等.卡度尼利单抗治疗复发性/晚期宫颈癌的有效性和安全性[J].现代妇产科进展,2024,33(2):133-136.
2026, Vol. 32 
冀公网安备13080202000786号